أيرلندا - الإنجليزية - HPRA (Health Products Regulatory Authority)

hikma farmaceutica (portugal) sa - dobutamine hydrochloride - concentrate for soln for inf - 50 mg/ml

أيرلندا - الإنجليزية - HPRA (Health Products Regulatory Authority)

hikma farmaceutica (portugal) sa - dobutamine hydrochloride - solution for infusion - 5 mg/ml

أيرلندا - الإنجليزية - HPRA (Health Products Regulatory Authority)

hikma farmaceutica (portugal) sa - dobutamine hydrochloride - solution for infusion - 5 mg/ml

أيرلندا - الإنجليزية - HPRA (Health Products Regulatory Authority)

hikma farmaceutica (portugal) sa - dobutamine hydrochloride - concentrate for soln for inf - 12.5 mg/ml

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - benztropine mesylate (unii: wmj8tl7510) (benztropine - unii:1nhl2j4x8k) - for use as an adjunct in the therapy of all forms of parkinsonism (see dosage and administration ). useful also in the control of extrapyramidal disorders (except tardive dyskinesia - see precautions ) due to neuroleptic drugs (e.g., phenothiazines). hypersensitivity to any component of benztropine mesylate. because of its atropine-like side effects, this drug is contraindicated in pediatric patients under three years of age, and should be used with caution in older pediatric patients.

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - phentolamine mesylate (unii: y7543e5k9t) (phentolamine - unii:z468598hbv) - phentolamine mesylate 5 mg in 1 ml - phentolamine mesylate for injection is indicated for the prevention or control of hypertensive episodes that may occur in a patient with pheochromocytoma as a result of stress or manipulation during preoperative preparation and surgical excision. phentolamine mesylate for injection is indicated for the prevention or treatment of dermal necrosis and sloughing following intravenous administration or extravasation of norepinephrine. phentolamine mesylate for injection is also indicated for the diagnosis of pheochromocytoma by the phentolamine blocking test. myocardial infarction, history of myocardial infarction, coronary insufficiency, angina, or other evidence suggestive of coronary artery disease; hypersensitivity to phentolamine or related compounds.

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - acetazolamide sodium (unii: 429zt169uh) (acetazolamide - unii:o3fx965v0i) - acetazolamide 500 mg - for adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies (petit mal, unlocalized seizures); chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. hypersensitivity to acetazolamide or any excipients in the formulation. since acetazolamide is a sulfonamide derivative, cross sensitivity between acetazolamide, sulfonamides and other sulfonamide derivatives is possible. acetazolamide for injection therapy is contraindicated in situations in which sodium and/or potassium blood serum levels are depressed, in cases of marked kidney and liver disease or dysfunction, in suprarenal gland failure, and in hyperchloremic acidosis. it is contraindicated in patients with cirrhosis because of the risk of development of hepatic encephalopathy. long-term administration of acetazolamide for injection is contraindicated in patients with chronic noncongestive angle-closure glaucoma since it may permit organic closure of the angle to occur while the worsening glaucoma is masked by lowered intraocular pressure.

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - acetazolamide sodium (unii: 429zt169uh) (acetazolamide - unii:o3fx965v0i) - for adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies (petit mal, unlocalized seizures); chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. hypersensitivity to acetazolamide or any excipients in the formulation. since acetazolamide is a sulfonamide derivative, cross sensitivity between acetazolamide, sulfonamides and other sulfonamide derivatives is possible. acetazolamide therapy is contraindicated in situations in which sodium and/or potassium blood serum levels are depressed, in cases of marked kidney and liver disease or dysfunction, in suprarenal gland failure, and in hyperchloremic acidosis. it is contraindicated in patients with cirrhosis because of the risk of development of hepatic encephalopathy. long-term administration of acetazolamide is contraindicated in patients with chronic noncongestive angle-closure glaucoma since it may permit organic closure of the angle to occur while the worsening glaucoma is masked by lowered intraocular pressure.

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k) - acute infections caused by susceptible strains of pseudomonas aeruginosa. polymyxin b sulfate is a drug of choice in the treatment of infections of the urinary tract, meninges, and bloodstream caused by susceptible strains of ps. aeruginosa. it may also be used topically and subconjunctivally in the treatment of infections of the eye caused by susceptible strains of ps. aeruginosa . it may be indicated in serious infections caused by susceptible strains of the following organisms, when less potentially toxic drugs are ineffective or contraindicated: h influenzae , specifically meningeal infections. escherichia coli , specifically urinary tract infections. aerobacter aerogenes , specifically bacteremia. klebsiella pneumoniae , specifically bacteremia. note: in meningeal infections, polymyxin b sulfate should be administered only by the intrathecal route. to reduce the development of drug-resistant bacteria and maintain the effectiveness of polymyxin b and other antibacterial drugs, polymyxin b should be used

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - cyanocobalamin (unii: p6yc3eg204) (cyanocobalamin - unii:p6yc3eg204) - cyanocobalamin 1000 ug in 1 ml - cyanocobalamin is indicated for vitamin b12 deficiencies due to malabsorption which may be associated with the following conditions: addisonian (pernicious) anemia gastrointestinal pathology, dysfunction, or surgery, including gluten enteropathy or sprue, small bowel bacteria overgrowth, total or partial gastrectomy fish tapeworm infestation malignancy of pancreas or bowel folic acid deficiency it may be possible to treat the underlying disease by surgical correction of anatomic lesions leading to small bowel bacterial overgrowth, expulsion of fish tapeworm, discontinuation of drugs leading to vitamin malabsorption (see drug interactions ), use of a gluten-free diet in nontropical sprue, or administration of antibiotics in tropical sprue. such measures remove the need for long-term administration of cyanocobalamin. requirements of vitamin b12 in excess of normal (due to pregnancy, thyrotoxicosis, hemolytic anemia, hemorrhage, malignancy, hepatic and renal disease) can usually be met with oral supplementation. cyanocobalamin injection, usp is also suitable for the vitamin b12 absorption test (schilling test ). sensitivity to cobalt and/or vitamin b12 is a contraindication.